Prof. Jialei Wang 王佳蕾
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of chest tumors, including lung and esophageal cancer. Expertise in chemotherapy, targeted therapy, comprehensive care, and management of chemotherapy side effects.
Dr. Wang is Chief Physician, Professor, and Master’s Supervisor at Fudan University Shanghai Cancer Center, serving as Director of the Chest Tumor Department and Deputy Director of the Fudan Chest Tumor Institute. A visiting scholar at MD Anderson Cancer Center, Dr. Wang leads basic and clinical research on chest malignancies, supported by grants from the National Natural Science Foundation and Shanghai municipal agencies.
Professional roles
- Vice Chair, Youth Committee of Clinical Chemotherapy Professional Committee, China Anti-Cancer Association
- Chair, Lung Cancer Professional Committee, Shanghai Female Physicians Association
- Member, Non-Small Cell Lung Cancer, Vascular Targeting, and Geriatric Oncology Committees, Chinese Society of Clinical Oncology (CSCO)
- Editorial Board Member, Chinese Medical Journal (English Edition) and Chinese Journal of Metastatic Cancer
Name order: in Chinese the family name comes first (Wang Jialei). Papers usually list the name as Jialei Wang or Wang J.
Selected publications
92 papers on PubMed matched by name and affiliation; 30 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Immunother Cancer, 2026 (senior author): Plasma cell-free RNA ITGB3 is associated with long-term clinical benefit in patients with non-small cell lung cancer receiving immunochemotherapy. PubMed 42875050
- Sci Adv, 2026 (senior author): Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. PubMed 42726875
- Transl Lung Cancer Res, 2025 (senior author): Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study. PubMed 41510395
- Transl Lung Cancer Res, 2025 (senior author): Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers. PubMed 41234598
- J Thorac Dis, 2025 (senior author): First-line serplulimab-based immunochemotherapy in elderly patients with extensive-stage small cell lung cancer: a multicenter, real-world study. PubMed 40529764
- Front Immunol, 2025 (senior author): Small extracellular vesicle miRNAs as biomarkers for predicting antitumor efficacy in lung adenocarcinoma treated with chemotherapy and checkpoint blockade. PubMed 40230863
- Transl Lung Cancer Res, 2024 (senior author): EGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAF(V600E) mutation: a multi-center real-world experience in China. PubMed 39830741
- Front Immunol, 2024 (senior author): Plasma extracellular vesicle long RNA profiling identifies a predictive signature for immunochemotherapy efficacy in lung squamous cell carcinoma. PubMed 39161762
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion